Human influenza
Drug research and approvals for human influenza: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 124 studies of human influenza are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 124
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaNCT07943390 · Phase 3 · Boryung Biopharma Co., Ltd. · starts Nov 1, 2026
- A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and OlderNCT07933458 · Not reported · Ab&B Bio-tech Co., Ltd.JS · starts Sep 4, 2026
- CEDRN Pandemic Preparedness RegistryNCT07933861 · Not reported · University of British Columbia · starts Sep 1, 2026
- High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting…NCT07926217 · Phase 2 · Sung-Han Kim · starts Nov 2, 2026
- Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in HumansNCT07914673 · Phase 4 · Washington University School of Medicine · starts Sep 25, 2026
- Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza VaccinationNCT07910266 · Phase 4 · University of Missouri-Columbia · starts Oct 1, 2026
- Intradermal Influenza VaccinationNCT07908329 · Early Phase 1 · Yale University · starts Oct 1, 2026
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant…NCT07890454 · Phase 3 · Sanofi · starts Oct 28, 2026
- A Study of Updated mRNA Seasonal Influenza VaccinesNCT07884175 · Phase 4 · ModernaTX, Inc. · starts Oct 15, 2026
Approved 20
- OseltamivirNeuraminidase inhibitor
- ZanamivirNeuraminidase inhibitor
- PeramivirNeuraminidase inhibitor
- Baloxavir marboxilPolymerase acidic protein inhibitor
- AcetaminophenCyclooxygenase inhibitor
- IbuprofenCyclooxygenase inhibitor
- AmantadineGlutamate [NMDA] receptor antagonist
- RimantadineInfluenza virus A matrix protein M2 inhibitor
- PseudoephedrineNorepinephrine transporter releasing agent
- Influenza b virus hemagglutininHemagglutinin vaccine antigen
- Influenza a virus, inactivated whole virionBiological vaccine - induces immune response
- Influenza a virus, split virionBiological vaccine - induces immune response
- Influenza b virus, split virionBiological vaccine - induces immune response
- Influenza a virus, inactivated neuraminidaseNeuraminidase vaccine antigen
- Influenza b virus, inactivated neuraminidaseNeuraminidase vaccine antigen
- Influenza a virus hemagglutininHemagglutinin vaccine antigen
- Influenza b virus, inactivated hemagglutininHemagglutinin vaccine antigen
- Influenza b virus, live attenuatedBiological vaccine - induces immune response
- Influenza a virus, live attenuatedBiological vaccine - induces immune response
- Influenza a virus, inactivated hemagglutininHemagglutinin vaccine antigen
Phase 3 12 of 49
- Influenza virus vaccineBiological vaccine - induces immune response
- Laninamivir octanoateNeuraminidase inhibitor
- NitazoxanidePyruvate:ferredoxin oxidoreductase inhibitor
- FavipiravirRNA-directed RNA polymerase inhibitor
- ImiquimodToll-like receptor 7 agonist
- MoxifloxacinTopoisomerase IV inhibitor
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- EnalaprilAngiotensin-converting enzyme inhibitor
- FluoxetineSerotonin transporter inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- SirolimusFK506-binding protein 1A inhibitor
Phase 2 12 of 17
- DAS-181Glycosaminoglycans binding agent
- MEDI-8852Hemagglutinin binding agent
- VIS-410Hemagglutinin inhibitor
- DiridavumabHemagglutinin inhibitor
- TCN-032Matrix protein 2 inhibitor
- PimodivirPolymerase basic protein 2 inhibitor
- BaloxavirPolymerase acidic protein inhibitor
- MolnupiravirRNA disrupting agent
- RibavirinInosine-5'-monophosphate dehydrogenase 1 inhibitor
- ChloroquineFerriprotoporphyrin IX inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- DiltiazemVoltage-gated L-type calcium channel blocker
Phase 1 or earlier 12 of 15
- Aluminum hydroxideAntacid
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- Interferon alfaCON-1Interferon alpha/beta receptor agonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- PitavastatinHMG-CoA reductase inhibitor
- DigoxinSodium/potassium-transporting ATPase inhibitor
- FGI-101-1A6Tumor susceptibility gene 101 protein inhibitor
- ResiquimodToll-like receptor 8 agonist
- Interferon
- Polyglyconate
- Radavirsen
How its trials ended
2,105 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 638 whose ending is known, 75% met their primary endpoint, 6% missed it and 19% stopped early.
- Completed, result not reported1,16455%
- Met its primary endpoint48023%
- Ongoing1638%
- Status unknown1407%
- Stopped: other or unclear744%
- Missed its primary endpoint392%
- Stopped: enrollment or feasibility181%
- Stopped: lack of efficacy131%
- Stopped: sponsor or business decision9<1%
- Stopped: funding4<1%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA